$BIXT News
Last published 1w ago
- 1w agoBIXTBioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf MarketsGlobeNewswireNon-systemic, pre-meal chewable nutraceutical designed to help blunt post-meal blood sugar spikes enters a region where roughly 7.5 million adults in the UAE, Saudi Arabia and Kuwait are living with diabetes Boston,
- 3w agoBIXTBioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood SugarGlobeNewswireFinished inventory of both products has been manufactured; Company is finalizing go-to-market plans Boston, MA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the
- 3mo agoBIXTBioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial IntelligenceGlobeNewswireOnce-weekly intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported during treatment BOSTON, MA, Aug. 11, 2026 (GLOBE NEWSWIRE) --
- 3mo agoBIXTBioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis DrugsGlobeNewswireCompany's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE
- 3mo agoBIXTBioxytran Announces Publication of Corporate Research Report by Globe Small Cap ResearchGlobeNewswireReport discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran’s A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS,
- 5mo agoBIXTBioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25GlobeNewswireBrain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB:BIXT), a biotechnology company developing
- 8mo agoBIXTBioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-MGlobeNewswireCompany Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB:BIXT)
- 9mo agoBIXTBioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytranGlobeNewswireBOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB:BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial
- 9mo agoBIXTBioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based TherapeuticsGlobeNewswireNEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia,
- 12mo agoBIXTBioxytran Announces Initiation of Coverage of its Stock by Independent ResearchGlobeNewswireBOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer's, and viral infections is
- 1y agoBIXTBioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral DrugGlobeNewswireData from the dose optimization trial expected soonProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the
- 1y agoBIXTBioxytran Unveils Revolutionary Precision Diagnostics on Tissue OxygenationGlobeNewswireGame changer for stroke, Alzheimer's, and beyond Shifting from peripheral to tissue-specific oxygenation monitoring BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the
- 1y agoBIXTBioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection TreatmentGlobeNewswire- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"),
- 1y agoBIXTBioxytran Secures a Source of GMP Quality Camel HemoglobinGlobeNewswire- First use of camel hemoglobin as a universal oxygen carrier - Unique properties make it an ideal ingredient for oxygen transport BOSTON, MASSACHUSETTS, June 18, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC.
- 1y agoBIXTBioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During StrokesGlobeNewswireMongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a
- 1y agoBIXTBioxytran's Antiviral Breakthrough Featured in University of Georgia's $100M HPAI Poultry Innovation Grand Challenge SubmissionGlobeNewswirePHM23 was one of a handful of molecules chosen by the universityBird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN,
- 1y agoBIXTBioxytran Completes Dose Optimization of Antiviral, ProLectin-MGlobeNewswireBOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful
- 1y agoBIXTBioxytran Marks 50 years of Mitochondrial Research with BXT-25 AdvancementsGlobeNewswire- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases - Leading drug candidate ProLectin-M targets galectins in viral infections including
- 1y agoBIXTBioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in ChickensGlobeNewswireIn Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology
- 1y agoBIXTBioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving BillionsGlobeNewswireNew water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks BOSTON, MASSACHUSETTS, March 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT)
- 1y agoBIXTBioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical DevelopmentGlobeNewswire- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN,
- 1y agoBIXTBioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy DrugsGlobeNewswireBOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis,
- 1y agoBIXTBioxytran Announces Government Interest After Initial BARDA Techwatch Light MeetingGlobeNewswireBOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis,
- 2y agoBIXTBioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen CarrierGlobeNewswireThe Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage
- 2y agoBIXTBioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's PatientsGlobeNewswireBXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing drugs to treat stroke
- 3y agoBIXTBioxytran Interview at the Emerging Growth ConferenceGlobeNewswireThursday, October 5, 2023 10:15 am –10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company
- 3y agoBIXTDVNCFODIIRDRSF+5Presenting on the Emerging Growth Conference on May 3 Register NowGlobeNewswireMIAMI, May 02, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 55th Emerging Growth Conference on May 3, 2023. The Emerging Growth Conference
- 3y agoBIXTBioxytran Interview at the Emerging Growth ConferenceGlobeNewswireWednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a
- 3y agoBIXTBioxytran Interview at the Emerging Growth ConferenceGlobeNewswireWednesday, April 5, 2023 10:50 am –11:20am ESTDiscussion of Peer Reviewed Article and Long COVID BOSTON, MASSACHUSETTS, April 03, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage
- 3y agoBIXTProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial VirusGlobeNewswireActivity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the
- 3y agoBIXTNature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral DrugGlobeNewswireBOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, other viral
- 3y agoBIXTBioxytran to Appear on ClearThink IR's Virtual Live EventGlobeNewswire- Wednesday, February 15th, 2023 12:00 EST - Virtual Fireside Chat via Paltalk Platform BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage
- 3y agoBIXTBioxytran Receives Approval to Initiate Trials with ProLectin-IGlobeNewswireBOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral
- 3y agoBIXTBioxytran Interview at the Emerging Growth ConferenceGlobeNewswire- Wednesday, January 25, 2023 10:50 am –11:20am EST - Discussion of the Biotech Showcase Conference BOSTON, MASSACHUSETTS, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a
- 3y agoBIXTCrystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 TrialGlobeNewswireTrial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28, 2022 (GLOBE NEWSWIRE)
- 3y agoBIXTBioxytran Establishes Indian Subsidiary in Preparation of CommercializationGlobeNewswireBOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral
- 3y agoBIXTBioxytran Interview at the Emerging Growth ConferenceGlobeNewswireWednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology
- 3y agoBIXTBioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise AnalyticsGlobeNewswireBOSTON, MASSACHUSETTS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT), a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in
- 3y agoBIXTBNTXINOMRNA+2While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat SubvariantsPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., Nov. 16, 2022 /PRNewswire/ -- The COVID-19 pandemic has devastated the world and impacted millions of people… as a result, the demand for the creation of
- 3y agoBIXTBioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-printPR NewswireComplete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of viral load in 88% of patients at day 3 vs 0% in placebo (p=.001) Treated population experienced no viral
- 4y agoBIXTBioxytran Scientific Advisor Releases New Book on Brain MetabolismGlobeNewswireThe book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen. BOSTON, MASSACHUSETTS, Oct. 25,
- 4y agoBIXTNovel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 CoronavirusGlobeNewswireProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other